-
April 10, 2026
R & D
Nippon Shinyaku Enters Collaboration with xFOREST Therapeutics on Drug Discovery Research Targeting RNA Structures
-
March 18, 2026
Pharmaceuticals
Launch of ELZONRIS® I.V. Injection for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan
-
March 18, 2026
Pharmaceuticals
Nippon Shinyaku start co-promotion activities of OPSUMIT® Pediatric Dispersible Tablets 1mg and 2.5mg for the Treatment of Pulmonary Arterial Hypertension
-
March 11, 2026
R & D
CAP-1002：Capricor Therapeutics Announces Establishment of New PDUFA Date
-
February 24, 2026
Pharmaceuticals
Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL
-
February 10, 2026
R & D
RGX-121: REGENXBIO received Complete Response Letter from the U.S. FDA for Biologics License Application for mucopolysaccharidosis type II
-
February 09, 2026
Corporate
Notice Regarding Executive Personnel Changes
-
February 09, 2026
Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025
-
January 29, 2026
R & D
Regulatory Update on RGX-111 and RGX-121
